Xenon Pharmaceuticals Inc.
XENE
$58.76
-$0.79-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.24% | 2.81% | -15.80% | -7.31% | -30.22% |
| Total Depreciation and Amortization | -4.94% | -3.93% | -4.68% | 1.42% | -4.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.71% | 14.06% | 4.88% | -21.36% | 15.32% |
| Change in Net Operating Assets | 171.92% | -137.69% | 80.70% | 89.21% | 121.51% |
| Cash from Operations | -7.30% | -9.10% | -13.56% | -11.71% | -4.19% |
| Capital Expenditure | -106.77% | 58.18% | -13.17% | -78.98% | -265.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.71% | -746.11% | 62.36% | -52.91% | 138.52% |
| Cash from Investing | 18.67% | -749.60% | 62.72% | -53.16% | 138.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 642.50% | 4,710.89% | 3,530.77% | -94.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 642.50% | 4,710.89% | 3,530.77% | -94.35% |
| Foreign Exchange rate Adjustments | 301.54% | -25.00% | -1,633.33% | -100.95% | 1,087.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -222.97% | 266.30% | 406.63% | -264.85% | 171.86% |